January 2016
Prof Shoumo Bhattacharya, Cardiovascular Medicine
Targeting the chemokine system in breast and metastatic colon cancer using novel Evasins identified from tick saliva
Prof Colin Goding, Ludwig Cancer Research
Prof Sarah Blagden, Department of Oncology
Translation reprogramming as a therapeutic target in cancer
Dr Bart Cornelissen, Department of Oncology
Prof Veronique Gouverneur, Department of Chemistry
PET Imaging with PARP inhibitors
Dr Oleg Fedorov, Prof Paul Brennan, SGC
Prof Udo Oppermann, NDORMS
Towards development of histone methyl-lysine reader inhibitors for SPIN1- a novel molecular target in liposarcoma
Prof Udo Oppermann, NDORMS
Dr Karthik Ramasamy, OUH NHS Foundation Trust
Tool development to monitor immune suppressive mechanisms by epigenetic inhibitors in multiple myeloma
Dr James Larkin, Prof Nicola Sibson, Department of Oncology
Metabolomic identification of melanoma and lung cancer patients with brain metastases
Dr Simon Lord, OUH NHS Foundation Trust
Dr Neel Patel, OUH NHS Foundation Trust
Dr Anderson Ryan, Department of Oncology
Repurposing cardiac perfusion imaging as a biomarker of anti-angiogenic and antimitochondrial therapy
Dr Benoit Van den Eynde, Ludwig Cancer Research
Developing viral vectored vaccines for MAGE-expressing tumours
Prof Nicholas Lakin, Department of Biochemistry
Identifying novel applications for the use of PARP inhibitors in cancer treatment
Prof Robert Gilbert, STRUBI
Prof Chris Norbury, Dunn School of Pathology
Prof Geoff Higgins, Department of Oncology
Development of improved inhibitors of cytoplasmic uridylyl transferases implicated in multiple types of cancer, including those of unmet need
Dr Eleftheria Dafni Pefani, Dr Eric O’Neill, Department of Oncology
Uncovering the crosstalk between RASSF1A and BLM to target cancer
Dr Yvonne Couch, RDM
Real-time electrical impedance assessment of barrier permeability responses to inflammatory mediators
Dr Catrine Johansson, Department of Chemistry
Structural and functional characterisation of the histone demethylase JMJD1C a potential therapeutic drug target in leukaemia
Dr Judith Nicholson, Prof Anne Kiltie, Department of Oncology
Mapping and validating clinically significant acetylation modifications in the DNA damage response pathway related to radiosensitisation mechanisms
Prof Stephen Faulkner, Department of Chemistry
Dr Bart Cornelissen, Dr Rebekka Hueting, Department of Oncology
Novel 89Zr chemistry for molecular imaging
Dr Lynn Quek, RDM
Lentiviral Barcoding of Primary Human AML Stem Cells
Dr Michael Holmes, Prof Zhenhming Chen, CTSU
Using novel metabolomics profiling for improved risk prediction and understanding of aetiology of pancreatic cancer
Dr Mariolina Salio, Prof Enzo Cerundolo, MRC Human Immunology Unit
Analysis of the T Cell repertoire in bladder cancer
Dr Ronan Broderick, Department of Oncology
Exploiting the potential on a novel human exonuclease required for homologous recombination in cancer therapy
Dr Richard Hopkinson, Department of Chemistry
Investigating the Molecular Mechanisms of Formaldehyde-induced Carcinogenicity
Prof Richard Gibbons, Dr Dennis Ptchelkine, WIMM
Determining the structure of the ATRX tumour suppressor complex